background
clear
need
vaccin
therapeut
potenti
biolog
weapon
mass
destruct
emerg
diseas
anthrax
caus
bacterium
bacillu
anthraci
use
biolog
warfar
agent
bioterrorist
weapon
previous
although
antibiot
therapi
effect
earli
stage
anthrax
infect
effect
expos
individu
becom
symptomat
due
b
anthraci
exotoxin
accumul
bipartit
exotoxin
major
contribut
factor
morbid
mortal
observ
acut
anthrax
infect
method
use
recombin
b
anthraci
protect
antigen
coval
coupl
novel
nontox
muramyl
dipeptid
ntmdp
deriv
hyperimmun
goat
three
time
cours
week
goat
plasmapheres
igg
fraction
affin
purifi
f
ab
deriv
character
vitro
vivo
protect
lethal
toxin
mediat
intox
result
igg
confer
protect
cell
toxin
neutral
assay
mice
expos
ld
bacillu
anthraci
ame
spore
intranar
inocul
demonstr
surviv
postinfect
administ
singl
bolu
dose
mgkg
bodi
weight
igg
h
post
spore
challeng
f
ab
fragment
retain
similar
neutral
protect
level
vitro
vivo
protect
afford
gmpgrade
caprin
immunotherapeut
postexposur
pilot
murin
model
suggest
could
use
effect
treat
postexposur
symptomat
human
anthrax
patient
follow
bioterror
event
result
also
indic
recombin
coupl
ntmdp
potent
induc
neutral
antibodi
suggest
would
promis
vaccin
candid
anthrax
eas
product
eas
coval
attach
immunostimulatori
activ
ntmdp
indic
would
superior
adjuv
alum
tradit
adjuv
vaccin
formul
bacillu
anthraci
caus
agent
anthrax
focu
much
research
attent
follow
releas
spore
us
mail
system
case
infect
result
death
caus
much
concern
regard
treatment
therapeut
vaccin
efficaci
recent
cdc
discontinu
administr
current
anthrax
vaccin
anthrax
vaccin
adsorb
ava
due
advers
side
effect
observ
larg
percentag
volunt
revoc
avail
vaccin
left
healthcar
worker
laboratori
personnel
first
respond
limit
mean
protect
follow
potenti
exposur
anthrax
spore
human
anthraci
bacilli
caus
three
type
infect
cutan
via
abras
skin
gastrointestin
ingest
spore
contamin
meat
inhal
spore
less
um
um
deposit
lung
mortal
rate
vari
form
diseas
cutan
anthrax
present
selflimit
treatabl
infect
case
fatal
rate
left
untreat
gastrointestin
infect
progress
rapidli
case
fatal
rate
inhal
anthrax
infect
rare
high
case
fatal
rate
even
antibiot
treatment
treatment
option
patient
present
symptom
inhal
anthrax
infect
limit
gener
ineffect
reduc
mortal
although
antibiot
therapi
effect
earli
stage
infect
effect
bipartit
exotoxin
major
contribut
factor
mortal
observ
acut
anthrax
infect
current
lack
approv
avail
vaccin
put
laboratori
worker
militari
personnel
first
respond
increas
risk
inhal
anthrax
anoth
terrorist
event
similar
anthrax
mail
occur
clearli
need
effect
vaccin
well
welltoler
econom
postexposur
therapeut
treatment
human
anthrax
infect
passiv
immunotherapi
nonchem
therapeut
provid
immedi
immun
infecti
agent
toxin
treatment
option
shown
effect
mani
diseas
includ
anthrax
biothreat
agent
sever
approach
use
previous
product
immunotherapeut
specif
b
anthraci
although
signific
drawback
pool
immun
serum
previous
vaccin
volunt
yield
highli
protect
antisera
small
quantiti
limit
use
sourc
therapeut
strateg
nation
stockpil
commerci
avail
product
monoclon
antibodi
highli
specif
limit
applic
singl
antigen
target
high
cost
associ
develop
limit
feasibl
mass
product
stockpil
past
anim
vaccin
success
use
gener
immunotherapeut
antiserum
specif
infecti
toxic
agent
includ
snake
venom
botul
toxin
ebola
viru
limit
quantiti
safeti
prevent
widespread
use
develop
human
therapeut
hors
provid
larg
amount
antiserum
costli
maintain
mice
rabbit
guinea
pig
inexpens
maintain
yield
limit
volum
antisera
goat
provid
renew
sourc
plasma
serum
howev
tradit
use
gener
passiv
immunotherapeut
plasmapheres
hyper
immun
goat
success
produc
liter
gmpgrade
antisera
follow
short
immun
schedul
immun
week
minim
cost
bacillu
anthraci
produc
two
separ
exotoxin
edema
toxin
edtx
lethal
toxin
letx
two
exotoxin
util
common
cell
bind
compon
term
protect
antigen
kda
bind
ubiquit
anthrax
toxin
receptor
atr
found
cell
surfac
bound
host
cell
surfac
furinlik
proteas
cleav
fulllength
inact
protein
activ
form
kda
therebi
expos
bind
site
catalyt
compon
exotoxin
edema
factor
ef
lethal
factor
lf
heptam
compos
three
lfef
moieti
form
cell
surfac
intern
via
receptor
mediat
endocytosi
subsequ
decreas
ph
within
endosom
caus
conform
chang
insert
endosom
membran
form
proteasest
pore
format
pore
allow
ef
lf
enter
cell
exert
toxic
effect
letx
form
combin
lf
respons
sever
intox
effect
anthrax
infect
ef
adenyl
cyclas
capabl
caus
sever
disregul
cellular
camp
level
lf
shown
zincdepend
metalloproteas
specif
mitogenactiv
protein
kinas
kinas
mapkk
capabl
disrupt
sever
cell
signal
cascad
howev
specif
mode
action
still
unclear
disrupt
bind
pa
atr
lf
would
disrupt
intern
function
letx
would
therebi
prevent
toxinmedi
death
host
follow
rapid
multipl
bacilli
immun
goat
recombin
coupl
novel
nontox
muramyl
dipeptid
deriv
ntmdp
capabl
induc
innat
humor
immun
induc
clot
even
administ
high
concentr
result
polyclon
antisera
confer
protect
vitro
vivo
intox
anthrax
lethal
toxin
letx
vivo
intranas
challeng
virul
b
anthraci
spore
recent
shown
passiv
transfer
goatderiv
antihiv
antibodi
fail
therapi
aid
patient
well
toler
safe
effect
order
circumv
hypersensit
reaction
associ
goat
igg
explor
use
f
ab
antibodi
lack
fc
region
igg
molecul
fc
region
igg
involv
activ
complement
patient
predevelop
sensit
goat
protein
may
higher
risk
develop
fatal
allerg
reaction
follow
administr
goatbas
antibodi
therapi
remov
fc
region
allow
retent
dimer
antigen
bind
site
increas
safeti
immunotherapeut
without
signific
loss
neutral
capabl
data
suggest
administr
goat
igg
f
ab
would
provid
efficaci
welltoler
passiv
immunotherapi
postexposur
treatment
acut
human
anthrax
infect
notabl
rapid
antisera
produc
goat
volum
antisera
gener
singl
plasmapheresi
addit
data
serv
proof
concept
rapid
inexpens
gmpgrade
immunotherapeut
produc
short
enough
timefram
emerg
diseas
event
like
sarscov
highpur
histidinetag
rlf
suppli
northeast
biodefens
center
protein
express
core
function
lethal
toxin
letx
form
combin
purifi
rlf
ww
ratio
dilut
steril
pb
purifi
suppli
virionyx
corpor
ltd
auckland
nz
caprin
immun
follow
novel
muramyl
dipeptid
adjuv
ntmdp
oxid
sodium
meta
period
h
excess
sodium
meta
period
remov
centrifug
follow
water
wash
mg
sodium
carbon
buffer
ph
ad
mg
activ
ntmdp
incub
overnight
room
temperatur
result
schiff
base
reduc
addit
ascorb
acid
achiev
ph
three
goat
immun
conjug
emulsifi
freund
complet
adjuv
subsequ
boost
three
addit
time
immunogen
freund
incomplet
adjuv
period
hyperimmun
plasma
collect
anim
two
week
follow
last
immun
plasma
pool
igg
purifi
use
standard
octano
acid
precipit
techniqu
purifi
igg
suppli
concentr
mgml
f
ab
fragment
gener
pepsin
digest
umg
igg
ph
glycin
buffer
h
reactiv
demonstr
use
ouchterloni
gel
diffus
assay
demonstr
reactiv
mgml
rabbit
antigoat
igg
data
shown
puriti
extent
digest
determin
sdspage
analysi
data
shown
elisa
perform
microtit
plate
coat
nm
mm
carbonatebicarbon
buffer
ph
final
coat
volum
plate
coat
h
wash
water
block
nonfat
milk
powder
antibodi
titer
measur
react
h
serial
dilut
igg
microtit
well
well
wash
water
react
h
horseradish
peroxidaselabel
rabbit
antigoat
igg
follow
one
water
wash
well
react
min
substrat
orthophenylenediamin
reaction
stop
addit
sulfur
acid
absorb
measur
nm
igg
titer
measur
express
reciproc
antibodi
dilut
produc
absorb
valu
equal
maximum
absorb
murin
macrophagelik
cell
obtain
american
type
cell
cultur
collect
atcc
cell
cultur
complet
medium
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
glutamax
penicillin
streptomycin
co
macrophagelik
cell
harvest
gentl
scrape
trypsin
seed
plate
densiti
cellswel
complet
medium
cell
incub
h
confluenc
achiev
medium
remov
cell
wash
steril
pb
addit
toxin
antisera
toxic
assay
letx
ad
cell
final
concentr
ng
ng
ng
ng
data
shown
protect
assay
ng
letx
tcec
combin
vari
dilut
igg
f
ab
incub
shake
h
prior
addit
per
well
cell
letx
alon
combin
antisera
incub
co
h
cell
viabil
determin
use
sigma
cell
growth
determin
kit
mttbase
assay
briefli
mtt
dye
ad
cell
incub
h
co
solubil
solut
ad
well
remov
media
cell
viabil
measur
nm
percent
rel
cell
viabil
calcul
ratio
letxtreat
cell
letx
untreat
control
cell
pb
percent
protect
confer
caprin
igg
f
ab
measur
follow
pb
igg
pb
ng
letx
purifi
rlf
kda
kda
show
high
product
puriti
signific
breakdown
product
sd
page
trypsin
digest
mass
spectroscopi
puriti
data
shown
vitro
bioactiv
letx
confirm
treat
murin
macrophagelik
cell
vari
dose
letx
ng
cell
viabil
determin
via
toxin
neutral
assay
cell
viabil
experi
establish
tcec
ng
letx
equival
nm
data
shown
dose
letx
within
rang
previous
report
tcec
base
data
subsequ
vitro
protect
assay
perform
tcec
equival
total
ng
letx
per
well
one
goal
studi
produc
larg
volum
high
titer
hyperimmun
goat
sera
short
period
time
goat
immun
four
time
day
period
day
subsequ
plasmapheres
day
total
igg
purifi
plasma
specif
confirm
western
blot
elisa
data
shown
valid
efficaci
immunogenadjuv
immun
schedul
igg
purif
method
establish
previous
antihiv
immunotherapeut
specif
titer
obtain
immun
goat
day
antibodi
titer
measur
elisa
react
serial
dilut
igg
nm
igg
demonstr
signific
titer
calcul
reciproc
dilut
produc
maximum
absorb
within
week
postimmun
reach
maximum
fourth
immun
fig
high
titer
polyclon
antisera
could
gener
littl
day
thu
establish
rapid
product
targetspecif
caprin
goat
igg
titer
day
initi
immun
ig
titer
immunotherapeut
use
novel
ntmdp
adjuv
achiev
protect
efficaci
igg
f
ab
deriv
evalu
letx
vitro
model
cell
expos
letx
dilut
igg
f
ab
mttbase
cell
viabil
assay
use
determin
percent
protect
describ
materi
method
control
includ
untreat
cell
ie
pb
substitut
letx
cell
treat
igg
alon
ig
letx
cell
treat
letx
alon
letx
letx
treat
cell
demonstr
statist
signific
decreas
cell
viabil
p
compar
untreat
pb
control
cell
standard
concentr
igg
effect
cell
viabil
data
shown
use
higher
concentr
igg
produc
signific
differ
cell
viabil
data
shown
result
confirm
caprin
igg
exhibit
inher
cytotox
effect
vitro
interfer
observ
cytotox
recombin
letx
cell
treat
vari
concentr
igg
exhibit
protect
letx
cytotox
dosedepend
manner
fig
cell
expos
five
separ
assay
four
replic
vari
dose
igg
ng
letx
h
igg
fulli
protect
cell
letx
mediat
cell
death
offer
minim
protect
letx
treat
control
cell
fig
treatment
letx
expos
cell
f
ab
demonstr
equival
protect
compar
igg
fig
lower
dose
observ
diminish
protect
afford
f
ab
compar
whole
igg
data
confirm
rapidli
produc
caprin
immunotherapeut
either
whole
igg
despeci
f
ab
fragment
elicit
complet
protect
letxmedi
cytotox
vitro
efficaci
igg
f
ab
immunotherapeut
establish
intraperiton
letxchalleng
mous
model
fig
iggtreat
group
also
show
protect
remaind
studi
abil
goat
deriv
passiv
immunotherapeut
protect
vivo
letx
challeng
suggest
potenti
use
therapeut
intervent
human
sinc
model
simul
symptomat
patient
specul
immunotherapeut
could
use
efficaci
postexposur
prevent
mortal
evalu
postexposur
efficaci
igg
mous
model
inhal
anthrax
use
femal
swiss
webster
mice
challeng
virul
b
anthraci
spore
via
intranas
infect
rout
mice
receiv
ld
b
anthraci
ame
spore
instil
nare
control
mice
receiv
salin
h
postchalleng
twentyfour
hour
postchalleng
test
group
receiv
mgkg
caprin
igg
intraperiton
inject
postinfect
pi
control
mice
surviv
mice
treat
igg
still
aliv
fig
day
anoth
mice
group
succumb
diseas
mortal
observ
remain
studi
one
test
group
also
receiv
lowdos
ciprofloxacin
examin
synergist
effect
postexposur
treatment
fig
mice
treat
antibiot
alon
exhibit
surviv
rate
end
studi
pi
surviv
igg
treat
mice
drop
day
pi
remain
complet
studi
concomit
administr
ciprofloxacin
twice
daili
day
igg
singl
bolu
h
pi
complet
protect
mice
day
fig
ciprofloxacin
administ
ciprofloxacin
treatment
stop
surviv
decreas
level
compar
igg
treatment
alon
result
confirm
potenti
passiv
transfer
immun
hour
post
exposur
b
anthraci
spore
suggest
parallel
treatment
antibiot
significantli
enhanc
surviv
mani
group
shown
efficaci
polyclon
animalderiv
sera
use
passiv
immunotherapeut
anthrax
infect
howev
group
reli
smaller
anim
model
eg
mice
rabbit
guinea
pig
gener
antisera
smaller
anim
typic
termin
bled
order
produc
larger
volum
serum
yield
termin
bleed
typic
rang
ml
mice
ml
termin
bled
rabbit
larg
number
anim
requir
produc
therapeut
quantiti
need
use
medic
countermeasur
stockpil
eg
sn
make
anim
model
prohibit
expens
caprin
plasmapheresi
requir
anim
euthanizedtermin
bled
order
gener
larg
volum
antisera
addit
goat
plasmapheres
four
time
per
year
sever
year
make
nearli
endless
sourc
antisera
plasmapheresi
three
goat
gener
liter
serum
within
short
time
frame
addit
goat
use
produc
materi
part
certifi
pathogenfre
herd
antisera
produc
gmp
grade
compar
produc
igg
hiv
previous
approv
clinic
trial
human
previous
approv
ava
anthrax
vaccin
requir
seri
six
immun
follow
annual
boost
use
novel
nontox
mdp
adjuv
enabl
gener
extrem
hightit
antiserum
follow
two
immun
although
current
studi
igg
isol
goat
immun
four
time
optim
immun
regiment
may
abl
gener
efficaci
immunotherapeut
fewer
immun
thu
shorten
product
time
cost
also
emphas
data
present
use
nonaffinitypurifi
igg
f
ab
studi
underway
evalu
efficaci
affin
purifi
materi
may
significantli
reduc
amount
materi
requir
offer
signific
protect
anim
human
f
ab
antibodi
use
treatment
rattlesnak
bite
bee
sting
evalu
potenti
treat
sever
infecti
diseas
includ
respiratori
synciti
viru
rsv
mani
monoclon
antibodi
mab
gener
specif
anthrax
protect
antigen
major
mab
demonstr
signific
protect
postexposur
appear
requir
blend
sever
mab
order
reduc
mortal
associ
anthrax
infect
recent
studi
use
monoclon
antibodi
anthrax
protect
antigen
demonstr
requir
fc
portion
antibodi
order
retain
neutral
capabl
polyclon
immunotherapeut
retain
similar
neutral
level
vitro
vivo
remov
fc
region
pepsin
vivo
protect
letx
cytotox
figur
vivo
protect
letx
cytotox
percent
surviv
femal
balbc
mice
treat
letx
ip
inject
follow
minut
later
mgkg
igg
f
ab
antibodi
per
group
control
mice
salin
group
receiv
letx
follow
salin
mice
observ
twice
daili
sign
ill
distress
surviv
mice
euthan
day
postchalleng
p
logrank
test
digest
find
consist
data
polyclon
antiserum
indic
f
ab
retain
compar
neutral
protect
abil
full
length
igg
util
f
ab
antisera
deriv
goat
reduc
potenti
sideeffect
associ
patient
preexist
sensit
goat
protein
addit
patient
requir
multipl
treatment
anim
deriv
therapeut
may
also
increas
risk
develop
allerg
hypersensit
use
f
ab
antibodi
fragment
decreas
risk
increas
overal
safeti
immunotherapeut
multipl
use
within
larg
popul
work
shown
pharmaceuticalgrad
goat
polyclon
immunotherapeut
specif
anthrax
protect
antigen
rapidli
produc
larg
quantiti
three
goat
immun
four
time
day
period
produc
liter
gmp
grade
high
titer
antisera
capabl
neutral
anthrax
lethal
toxin
vitro
vivo
importantli
passiv
transfer
goatderiv
antibodi
h
postexposur
virul
anthrax
spore
provid
mice
substanti
surviv
advantag
untreat
mice
synergist
effect
seen
concomit
antibiot
treatment
although
level
protect
return
level
observ
igg
treatment
alon
antibiot
therapi
discontinu
indic
combin
treatment
approach
patient
present
clinic
sign
anthrax
infect
could
overal
increas
surviv
rate
associ
symptomat
diseas
addit
immunotherapeut
easili
produc
quantiti
larg
enough
fulfil
requir
nation
medic
countermeasur
stockpil
nontox
mdp
adjuv
develop
easili
produc
amen
coval
attach
antigen
importantli
render
toxin
pathogen
inact
coupl
molecul
use
novel
adjuv
improv
vaccin
develop
qualiti
control
addit
elicit
significantli
higher
immun
respons
standard
adjuv
portion
studi
fund
virionyx
corpor
ltd
hold
patent
right
nontox
mdp
adjuv
vivo
protect
intranas
virul
anthrax
challeng
figur
vivo
protect
intranas
virul
anthrax
challeng
percent
surviv
femal
swiss
webster
mice
per
group
infect
ld
b
anthraci
ame
spore
intranas
inocul
control
mice
treat
salin
h
post
spore
challeng
via
intraperiton
inject
mice
monitor
twice
dailyfor
sign
ill
death
mice
treat
mgkg
igg
h
post
spore
challeng
via
intraperiton
inject
p
thelogrank
test
b
mice
treat
ciprofloxacin
alon
combin
igg
mgkg
h
post
spore
challeng
ciprofloxacin
administ
twice
daili
mgday
via
intraperitonealinject
first
six
day
post
spore
challeng
statist
signific
use
logrank
test
follow
igg
p
igg
ciprofloaxcin
p
ciprofloaxcin
p
